View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, Nov. 19 (HealthDay News) -- Ticagrelor may have more effective antiplatelet activity than clopidogrel, according to research presented this week at the American Heart Association Scientific Sessions, held from Nov. 14 to 18 in Orlando, Fla.
In one study, Paul Gurbel, M.D., of the Sinai Center for Thrombosis Research in Baltimore, and colleagues studied the effects of ticagrelor versus clopidogrel in 41 clopidogrel non-responders and 57 control responders. They found that ticagrelor was associated with superior platelet inhibition in both non-responders and responders, and that the drug overcame non-responsiveness to clopidogrel.
In a second study, the same group of researchers studied the effects of ticagrelor versus clopidogrel in 123 patients with stable coronary artery disease receiving aspirin. They found that ticagrelor achieved more rapid and sustained inhibition of platelet aggregation than clopidogrel, as well as prompt offset when ticagrelor was discontinued.
"Ticagrelor achieves more rapid and greater sustained inhibition of platelet aggregation than clopidogrel. Moreover, after drug cessation the antiplatelet effect of ticagrelor had a faster offset," the authors conclude. "These results suggest value of ticagrelor when treatment protocol calls for rapid platelet inhibition or prompt offset of effect."
Several authors reported financial and consulting relationships with AstraZeneca.
More Information - AHA
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top